Cabozantinib Versus Standard-of-Care Comparators in the Treatment of Advanced/Metastatic Renal Cell Carcinoma in Treatment-naïve Patients: a Systematic Review and Network Meta-Analysis

BACKGROUND: Cabozantinib has recently been evaluated as a first-line treatment in advanced renal cell carcinoma (aRCC). OBJECTIVE: To indirectly assess efficacy of cabozantinib versus standard-of-care (SoC) comparators in the first-line treatment of aRCC. METHODS: We conducted a systematic literatur...

Descripción completa

Detalles Bibliográficos
Autores principales: Schmidt, Elvira, Lister, Johanna, Neumann, Monika, Wiecek, Witold, Fu, Shuai, Vataire, Anne-Lise, Sostar, Jelena, Huang, Shengnan, Marteau, Florence
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2018
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5887000/
https://www.ncbi.nlm.nih.gov/pubmed/29492762
http://dx.doi.org/10.1007/s11523-018-0559-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5887000/
https://www.ncbi.nlm.nih.gov/pubmed/29492762
http://dx.doi.org/10.1007/s11523-018-0559-0

Ejemplares similares